 |
Health
Profile of England 2009 |
| |
Rising rates of diabetes (DoH, UK) |
| |
|
|
Diabetes
in the UK 2010 |
| |
Key statistics on diabetes (Diabetes UK) |
| |
|
|
Scottish
diabetes survey 2009 |
| |
The Scottish Diabetes Survey provides data on
the number of people with diabetes, the effects on their health,
and the progress being made to improve the delivery and outcomes
of care for diabetes (NHS, UK) |
| |
|
|
Management
of diabetes |
| |
This guideline provides recommendations based
on current evidence for best practice in the management of diabetes
(NHS Evidence Diabetes) |
| |
|
|
Good
clinical practice guidelines for care home residents with diabetes |
| |
A revision document prepared by a Task and
Finish Group of (Diabetes UK) |
| |
|
|
Structure
of insulin’s docking point identified |
| |
Walter and Eliza Hall Institute scientists have
determined the structure of a previously unseen part of the insulin
receptor, making possible new treatments for diabetes (Walter and
Eliza Hall Institute) |
| |
|
|
Key
Protein Links Insulin Action and Insulin Resistance in Diabetes |
| |
Biologists have long known that an enzyme called
the PI 3-kinase is a crucial actor in the main molecular pathway
for insulin signaling in cells. Researchers at Joslin Diabetes
Center now have uncovered startling evidence that one of the proteins
in this enzyme also drives a pathway with an opposite result—triggering a stress response that leads to insulin resistance ( Joslin Diabetes
Center) |
| |
|
|
Novo
Nordisk Bluesheet |
| |
Quarterly perspectives on diabetes and chronic
diesases (Novo Nordisk) |
| |
|
|
Impact
of Metformin-Induced Gastrointestinal Symptoms on Quality of
Life and Adherence in Patients with Type 2 Diabetes |
| |
Metformin-associated GI symptoms in patients
with T2DM lead to lower physical and mental HRQoL, which may result
in patient nonadherence or physician reluctance to optimally titrate
the metformin dose (Postgraduate Medicine) |
| |
|
|
Sanofi-Aventis
will move into diabetes glucose testing |
| |
The French drugmaker Sanofi-Aventis will broaden
their healthcare resources on Wednesday by moving into an agreement
to develop blood glucose monitors with AgaMatrix, a private American
firm (Diabetes.co.uk) |
| |
|
